GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Silexion Therapeutics Corp
The value of Silexion Therapeutics, an early-stage oncology company, is determined by the potential of its scientific developments. Its valuation in the private market depends on preclinical data and its ability to attract venture capital funding for further research.
Share prices of companies in the market segment - General oncology therapy
Silexion Therapeutics is a biopharmaceutical company focused on developing new cancer treatments. We've categorized it as a "General Oncology" company, and the chart below shows how investors value companies at the forefront of cancer treatment.
Broad Market Index - GURU.Markets
Silexion Therapeutics is a pharmaceutical company developing drugs to treat oncology. Its scientific research makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Silexion shares compare to the overall market.
Change in the price of a company, segment, and market as a whole per day
SLXN - Daily change in the company's share price Silexion Therapeutics Corp
For Silexion Therapeutics Corp., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical metric for assessing risk.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Silexion Therapeutics Corp. is an early-stage biotech company developing cancer therapies. Companies like these are extremely sensitive to research news. The chart below illustrates the extreme volatility typical of the oncology startup segment, providing context for assessing SLXN's risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Silexion Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Silexion Therapeutics Corp
Silexion Therapeutics Corp.'s year-over-year performance is a story of targeted cancer drug development. Its 12-month market cap depends entirely on progress in preclinical and early clinical trials, where the company must prove the potential of its scientific platform to create effective and safe drugs.
Annual dynamics of market capitalization of the market segment - General oncology therapy
As an early-stage biotech company, Silexion is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Silexion Therapeutics, an early-stage oncology company, is a pure venture capital investment. Its annual market capitalization dynamics are virtually unrelated to the broader market and depend entirely on lab news. Any positive signal about preclinical studies could trigger a sharp increase, but the risks are just as high.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Silexion Therapeutics Corp
Silexion is an oncology company. Its monthly performance is typical for early-stage biotech companies: it depends entirely on progress in its scientific developments. News about preclinical studies, patents, and funding are the main catalysts.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Silexion Therapeutics is an oncology company developing targeted therapies. Like many clinical-stage biotechs, its valuation is determined by trial data and approval prospects. The oncology sector's price reflects overall investor interest in new cancer treatments, which provides an important backdrop for assessing Silexion's risks and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Silexion Therapeutics is an early-stage oncology company. Its shares are extremely volatile and completely uncorrelated with the market. Any news about preclinical trials or funding can cause sharp movements. The stock price of such a company reflects speculative expectations, not fundamental trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Silexion Therapeutics Corp
Silexion Therapeutics, an early-stage oncology company, is highly speculative. Its weekly stock price is driven not by market trends, but by internal news: progress in preclinical trials, patent filings, and the company's ability to secure funding for further development.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Silexion Therapeutics is an early-stage oncology company focused on innovative treatments. Its stock moves in response to scientific news and research data, rather than general market trends. The chart below shows how its path diverges from the average biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Silexion Therapeutics is an early-stage oncology company. Its stock moves in response to scientific news and research data, rather than general market trends. The chart will show how its path diverges from the average market dynamics.
Market capitalization of the company, segment and market as a whole
SLXN - Market capitalization of the company Silexion Therapeutics Corp
Silexion Therapeutics' market capitalization reflects how investors value its oncology developments. Its dynamics will depend entirely on the progress of its research and the results of preclinical and clinical trials. Its extremely small scale reflects the company's very early stage of development and high speculative interest.
SLXN - Share of the company's market capitalization Silexion Therapeutics Corp within the market segment - General oncology therapy
Silexion Therapeutics is an early-stage oncology company. Its market share in the pharmaceutical sector is virtually nonexistent, which is typical for a preclinical company. Its market capitalization reflects investors' assessment of its scientific concept and team, rather than any tangible assets or revenue.
Market capitalization of the market segment - General oncology therapy
This chart shows the overall market capitalization of the entire oncology sector. For Silexion Therapeutics, which works on specific drugs, this line represents the scale of the ocean in which it operates. The chart's fluctuations reflect global investor sentiment toward the entire industry, against which the company is trying to prove the value of its developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Silexion Therapeutics is an oncology company developing a new generation of targeted therapy. Its market capitalization, like that of many biotech companies, is a bet on the success of its scientific research in the fight against cancer.
Book value capitalization of the company, segment and market as a whole
SLXN - Book value capitalization of the company Silexion Therapeutics Corp
Silexion Therapeutics is an oncology company, and its book value represents its financial cushion. It consists of cash allocated for clinical trials of new anti-cancer drugs. How has this "war chest" changed? The chart below shows.
SLXN - Share of the company's book capitalization Silexion Therapeutics Corp within the market segment - General oncology therapy
Silexion Therapeutics Corp. is an oncology company whose developments require a material base. These include modern laboratories and equipment for the research and development of targeted therapies for cancer treatment. The chart shows the company's share of the physical R&D infrastructure in this biopharma segment.
Market segment balance sheet capitalization - General oncology therapy
Silexion Therapeutics is likely a biotech company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Silexion Therapeutics' assets are not factories, but a scientific platform for developing a new class of drugs targeting hard-to-reach protein targets in cancer treatment. The book value reflects the capital and laboratory facilities for this fundamental research. The chart illustrates the scale of this biotech startup.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Silexion Therapeutics Corp
Silexion Therapeutics is an oncology company. Its market capitalization is a valuation of its scientific platform and pipeline of drug candidates. Investors are betting on its ability to develop a new, effective cancer treatment, creating a gap with its book value.
Market to book capitalization ratio in a market segment - General oncology therapy
Silexion Therapeutics is a biotech company developing cancer treatments. Its market capitalization in this chart represents investors' pure bet on the future success of its clinical trials, which is typical for early-stage companies.
Market to book capitalization ratio for the market as a whole
Silexion Therapeutics is an oncology company whose value stems from the potential of its scientific developments. Like many biotechs, its market valuation is a bet on future success in cancer treatment. This chart demonstrates the overall market sentiment toward risk and innovation, allowing one to gauge investor appetite for such stories.
Debts of the company, segment and market as a whole
SLXN - Company debts Silexion Therapeutics Corp
Silexion Therapeutics, an early-stage oncology company, relies entirely on venture capital to fund its preclinical research. At this stage, debt is not a primary source of funding. This graph reflects the initial development phase, when all investments are directed toward proof of concept.
Market segment debts - General oncology therapy
Silexion Therapeutics is an early-stage oncology company. For such companies, the primary goal is to raise funding for preclinical and early clinical trials. This chart reflects the financial model of a biotech startup that relies entirely on venture capital and grants to validate its scientific hypotheses.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Silexion Therapeutics Corp
Silexion Therapeutics is an oncology company developing new cancer treatments. At the clinical development stage, biotech companies have no revenue and are entirely dependent on external funding. This chart shows how Silexion leverages its expensive research, which carries high risks.
Market segment debt to market segment book capitalization - General oncology therapy
Silexion Therapeutics is an early-stage oncology company. For such companies, access to capital is a matter of survival and the ability to continue research. This chart provides insight into its financial structure. It compares its debt to the market capitalization of the entire biotech sector, which is comprised of many similar risky ventures.
Debt to book value of all companies in the market
Silexion Therapeutics is an early-stage oncology company developing targeted therapy drugs. Fundamental research in biotech requires significant investment and high risk. How heavily will the company rely on debt? This graph of total debt in the economy provides context for assessing the future financial risks of its business model.
P/E of the company, segment and market as a whole
P/E - Silexion Therapeutics Corp
Silexion Therapeutics is an oncology company developing therapies for the treatment of solid tumors. This chart reflects speculative investor interest in its scientific developments. The valuation is highly volatile and depends on any news regarding preclinical and clinical trials.
P/E of the market segment - General oncology therapy
Silexion Therapeutics Corp. is an oncology company developing therapeutics for the treatment of cancer. Its scientific platform and stage of development define its profile. This chart illustrates the average valuation in the oncology development sector, where investors evaluate scientific potential but also the high risks associated with clinical trials.
P/E of the market as a whole
Silexion Therapeutics Corp. is an oncology company with the potential to develop new cancer treatments, possibly based on an innovative scientific platform. This chart reflects investors' overall risk appetite. It helps understand whether SLXN's valuation reflects speculative interest in its research or follows broader trends in the biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Silexion Therapeutics Corp
Silexion Therapeutics is an early-stage oncology company developing cancer treatments. Like many biotech startups, its valuation is based on the future potential of its scientific platform. This chart reflects investors' speculative expectations regarding the success of its research and development, not current financial performance.
%20P%2FE%20Silexion%20Therapeutics%20Corp&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Silexion-Therapeutics-Corp&v=1772683325261 "Chart of the company's future (projected) P/E Silexion Therapeutics Corp")
Future (projected) P/E of the market segment - General oncology therapy
Silexion Therapeutics is an oncology company developing targeted therapies. Its future depends on the success of preclinical and clinical trials. The chart reflects speculative profitability forecasts in the sector. It allows one to compare how optimistic the market is about Silexion's scientific approach compared to other biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772683325293 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Silexion Therapeutics Corp. is an early-stage oncology company developing a new generation of targeted therapies. Its valuation depends entirely on future success in the laboratory and clinical trials. This overall risk appetite chart is a barometer of investor appetite for funding fundamental research with a very distant prospect of commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772683325302 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Silexion Therapeutics Corp
Silexion Therapeutics Corp. is likely an early-stage oncology biotech. Its financial metrics, as reflected in this chart, likely reflect initial investments in research and development of a new therapeutic platform or drug candidate, a standard path for companies in this industry.
Profit of companies in the market segment - General oncology therapy
Silexion Therapeutics Corp. is likely a development-stage oncology company. The name may indicate a focus on silencing or inhibiting specific genes or proteins that cause cancer. This chart reflects overall profitability in the oncology sector, where precision medicine and targeted therapies are the most promising areas.
Overall market profit
Silexion Therapeutics Corp. is an oncology company focused on research and development of new treatments. Like most biotech startups, its value is determined by the potential of its intellectual property, not by current cash flows. The company's business is not dependent on economic cycles, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Silexion Therapeutics Corp
Silexion Therapeutics is likely an early-stage oncology company. Its future revenue and profitability are entirely dependent on successfully advancing its candidates through the lengthy and expensive clinical trials process. This chart reflects analysts' highly speculative estimates of its scientific potential.
%20profit%20of%20the%20company%20Silexion%20Therapeutics%20Corp&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Silexion-Therapeutics-Corp&v=1772683325413 "Graph of future (projected) profit of the company Silexion Therapeutics Corp")
Future (predicted) profit of companies in the market segment - General oncology therapy
Silexion Therapeutics is an oncology company developing a new generation of inhibitors targeting specific mutations that cause cancer. This precision medicine approach may be effective where other treatments fail. This chart shows revenue projections for the oncology sector, helping to assess the potential of Silexion's targeted therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772683325442 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Silexion Therapeutics Corp. is a biotechnology company focused on developing drugs for the treatment of oncology. Its success depends on research results and capital raising. This graph, reflecting market profit expectations, influences the investment climate and investor willingness to finance risky projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772683325474 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Silexion Therapeutics Corp
Silexion Therapeutics is an early-stage oncology company. It has no revenue and is entirely focused on research. This chart does not reflect financial performance but rather represents speculative investor expectations based on their belief in the scientific potential of its developments.
P/S market segment - General oncology therapy
Silexion Therapeutics is an oncology company likely developing new cancer treatments, possibly using targeted or immune therapies. Biotech companies in this field are at the forefront of science and attract significant investor attention. This chart displays the average revenue estimate for the sector, reflecting expectations for the fight against cancer.
P/S of the market as a whole
Silexion Therapeutics is an oncology company developing therapies targeting specific vulnerabilities in cancer cells. For these research-stage companies, this chart, which displays the average revenue estimate, highlights that their value is determined not by current sales, but by the potential of their scientific platform to develop new treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Silexion Therapeutics Corp
Silexion Therapeutics, as its name suggests, is an oncology company in development. Estimating future revenue for such a company is hypothetical but important. It reflects investors' faith in its scientific approach to cancer treatment and the long-term commercial potential of its drug candidates if they successfully complete clinical trials and receive regulatory approval.
%20P%2FS%20Silexion%20Therapeutics%20Corp&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Silexion-Therapeutics-Corp&v=1772683325574 "The graph of the company's future (projected) P/S Silexion Therapeutics Corp")
Future (projected) P/S of the market segment - General oncology therapy
Silexion Therapeutics is an oncology company developing targeted therapies that inhibit specific proteins that promote tumor growth. This chart reflects how investors view the company's future earnings relative to the biotech sector. It demonstrates the market's faith in its scientific approach and the potential of its drug candidates for treating various types of cancer.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772683325600 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Silexion Therapeutics is an oncology company developing a new generation of targeted therapies that overcome drug resistance. The company's future depends on the success of its platform in clinical trials. This market expectations chart reflects investor confidence that scientific advances will enable the creation of increasingly intelligent and effective cancer treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772683325619 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Silexion Therapeutics Corp
This section presents the financial activity of Silexion Therapeutics, an early-stage oncology company. There are currently no commercial revenues from product sales. Financial flows, if any, may be related to grants or seed funding for preclinical studies.
Sales of companies in the market segment - General oncology therapy
Silexion Therapeutics Corp. is an early-stage oncology company focused on developing targeted therapies. It currently has no sales revenue. Its valuation is based on the potential of its scientific research, and future revenue will depend on the successful advancement of its candidates through preclinical and clinical trials.
Overall market sales
Silexion Therapeutics Corp. is an early-stage oncology company developing a new generation of targeted therapies. Its prospects depend entirely on the success of preclinical and clinical trials. This overall market performance chart is not intended to reflect the company's valuation, which is determined by its scientific potential and intellectual property.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Silexion Therapeutics Corp
Silexion Therapeutics Corp. is a clinical-stage oncology company developing targeted therapies that target specific mutations in cancer cells. Future revenues depend on the success of its clinical programs. This chart reflects analyst expectations for potential sales of its drugs should they be approved and enter the personalized oncology market.
%20sales%20of%20the%20company%20Silexion%20Therapeutics%20Corp&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Silexion-Therapeutics-Corp&v=1772683325761 "Schedule of future (projected) sales of the company Silexion Therapeutics Corp")
Future (projected) sales of companies in the market segment - General oncology therapy
Silexion Therapeutics Corp. is an oncology company developing targeted therapies. This chart shows revenue forecasts for the entire oncology market. Is growth expected due to the emergence of new classes of drugs targeting specific tumor mutations? This reflects the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772683325787 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Silexion Therapeutics is an early-stage oncology company developing novel cancer treatments. Its value and future depend solely on scientific progress and preclinical and clinical trial data. General economic cycles, which can be tracked on this chart, do not affect the fundamental scientific risks or potential of its developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772683325812 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Silexion Therapeutics Corp
Silexion Therapeutics is an early-stage oncology company developing a new generation of inhibitors for cancer treatment. This chart reflects its financial performance at the preclinical stage. Profitability is a very distant goal, entirely dependent on the success of its scientific platform and its ability to attract significant funding for clinical trials.
Market segment marginality - General oncology therapy
Silexion Therapeutics Corp. is an early-stage biotechnology company developing cancer treatments. Its financial performance is entirely driven by research expenses. Profitability is a long-term prospect, dependent on successful completion of preclinical and clinical trials, a long and risky process.
Market marginality as a whole
Silexion Therapeutics, as its name suggests, is an oncology company. Its future depends entirely on the success of developing and commercializing anti-cancer drugs. This overall profitability chart reflects the investment climate, which determines how easily early-stage companies can raise capital for expensive research.
Employees in the company, segment and market as a whole
Number of employees in the company Silexion Therapeutics Corp
Silexion Therapeutics is an early-stage biotech company focused on cancer treatment. Like many startups in this field, its team is very small and consists of key scientific staff. This chart shows the minimal staff typical for companies in preclinical research and funding stages.
Share of the company's employees Silexion Therapeutics Corp within the market segment - General oncology therapy
Silexion Therapeutics is an early-stage oncology company developing therapies targeting specific mutations in cancer cells. Its team consists of a small group of highly specialized scientists. This graph shows its minimal market share, which is typical for biotech startups, where intellectual capital is more important than headcount.
Number of employees in the market segment - General oncology therapy
Silexion Therapeutics Corp. is an oncology company focused on developing targeted therapies for cancer treatment. The chart reflects its work in the general oncology sector. The company's approach involves targeting specific molecular targets in cancer cells, enabling the creation of more effective and less toxic drugs.
Number of employees in the market as a whole
Information about Silexion Therapeutics Corp (SLXN) is limited, as is typical for early-stage biotech companies. Their path is focused on research and development. Unlike the general employment picture in this chart, their staff consists of a small group of scientists, and their growth depends on successful progress through clinical trials and raising capital.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics is an oncology research company. If it's an early-stage biotech or has already closed down operations, this chart will show the residual market value (possibly from patents or cash) divided by what is likely a minimal workforce. This indicates whether the market values ββany of the company's remaining assets.
%20of%20the%20company%20Silexion%20Therapeutics%20Corp%20(SLXN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Silexion-Therapeutics-Corp-SLXN&v=1772683325897 "Chart of market capitalization per employee (in thousands of dollars) of the company Silexion Therapeutics Corp (SLXN)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Silexion Therapeutics (SLXN) is an oncology company developing targeted therapies. In biotech, valuation per employee is essentially a measure of intellectual property. A high valuation may indicate that the company's technology allows for highly precise targeting of cancer cells while minimizing harm to healthy tissue, a goal of modern oncology.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772683325930 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Silexion Therapeutics is an early-stage oncology company. Its valuation reflects investor expectations for its scientific platform. This chart shows a high cost per employee, as the valuation is based not on current revenue but on a speculative estimate of the potential of its research to develop new cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772683325971 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics is a very early, preclinical stage biotech company working on cancer treatments. This graph shows a significant loss per employee. It reflects the company's small number of scientists, who are pure cost centers, funded by venture capital to test hypotheses.
%20Chart%20Silexion%20Therapeutics%20Corp%20(SLXN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Silexion-Therapeutics-Corp-SLXN&v=1772683325989 "Company Profit Per Employee (in thousands of dollars) Chart Silexion Therapeutics Corp (SLXN)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Silexion Therapeutics Corp. is a biotech company focused on oncology. During the drug development stage, return per employee is often negative, but reflects the intensity of research. This chart allows investors to assess the company's current stage of development and its scientific potential compared to other biotech companies striving for breakthroughs.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772683326023 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Silexion Therapeutics is another early-stage oncology biotech. Their business is focused on discovering and developing new cancer drugs. Their value lies in their intellectual property and clinical trial data. This graph, showing the average market efficiency of their personnel, only highlights how far the biotech R&D model falls short of the economic average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772683326031 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics is an oncology company. For such companies in the development stage, this metric is typically zero. The graph represents a future opportunity: if their therapeutic approach is successful, revenue per employee could be astronomical, reflecting the enormous value of their research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Silexion-Therapeutics-Corp-SLXN&v=1772683326040 "Sales chart per company employee Silexion Therapeutics Corp (SLXN)")
Sales per employee in the market segment - General oncology therapy
Silexion Therapeutics is an early-stage (preclinical) biotech focused on developing cancer therapies. They have no commercial revenue. This chart, showing the average burn rate for the sector, serves as a barometer of SLXN's R&D staffing efficiency compared to other biotechs.
Sales per employee for the market as a whole
Silexion Therapeutics is a preclinical biotechnology company developing new approaches to cancer treatment. At this stage, the company has no commercial revenue and cannot generate it. This indicator reflects the company's status as an R&D startup, where all resources are invested in laboratory research.
Short shares by company, segment and market as a whole
Shares shorted by company Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics (SLXN) is an oncology company in the early, likely preclinical stage. This chart shows the number of short positions. "Shorts" here are bets that the company's science won't stand the test of time and that it, like thousands of others, won't even make it to serious clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Silexion-Therapeutics-Corp-SLXN&v=1772683326095 "Short Shares Chart for the Company Silexion Therapeutics Corp (SLXN)")
Shares shorted by market segment - General oncology therapy
Silexion (SLXN) - (likely private or delisted). In the oncology sector, the short interest chart reflects investor skepticism about the risks of clinical trials and the intense competition in cancer drug development, which is common across the industry.
Shares shorted by the overall market
Silexion (SLXN) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing SLXN won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics (SLXN) is a biotech company developing new cancer treatments. Like many companies in this space, it is in the early stages. This indicator measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on any positive signal or "oversold" (below 30) due to a lack of news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Silexion-Therapeutics-Corp-SLXN&v=1772683326115 "RSI 14 indicator chart for the company's stock Silexion Therapeutics Corp (SLXN)")
RSI 14 Market Segment - General oncology therapy
Silexion Therapeutics is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for the treatment of cancer. This sector is highly dependent on clinical trial data. This chart shows the overall "temperature" in the volatile oncology biotech sector. It helps separate SLXN's performance from the general "hype" or "disappointment" sweeping the industry.
RSI 14 for the overall market
Silexion Therapeutics (SLXN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLXN (Silexion Therapeutics Corp)
Silexion Therapeutics is a preclinical-stage oncology company developing a new class of immunotherapies (SIRPΞ± inhibitors) designed to help the immune system recognize and attack cancer. This chart shows the highly speculative average price target from analysts, based on their belief in this early-stage R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLXN-Silexion-Therapeutics-Corp&v=1772683326188 "A chart showing analyst consensus forecasts for the expected stock price. SLXN (Silexion Therapeutics Corp)")
The difference between the consensus estimate and the actual stock price SLXN (Silexion Therapeutics Corp)
Silexion Therapeutics is an early-stage biotech developing targeted cancer therapies. This chart shows the difference between the market valuation and the consensus estimate. For an R&D company, this gap reflects analysts' confidence in their scientific platform and the likelihood of success in preclinical studies.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLXN-Silexion-Therapeutics-Corp&v=1772683326191 "A chart showing the difference between the consensus forecast and the actual stock price. SLXN (Silexion Therapeutics Corp)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Silexion (SLXN) is an early-stage biotech developing targeted cancer therapies. This chart shows the overall expectations of analysts for the oncology sector. It reflects whether experts believe in new R&D breakthroughs or anticipate a "winter" in speculative biotech funding.
Analysts' consensus forecast for the overall market share price
Silexion Therapeutics is an early-stage biotech company focused on developing cancer treatments. This chart reflects the overall market "risk appetite." For Silexion, a high-risk company whose value is based on future expectations, overall market optimism (risk appetite) is critical to raising the capital needed for research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Silexion Therapeutics Corp
Silexion Therapeutics is likely a clinical-stage biotech R&D company focused on developing targeted therapies for cancer. This chart is a pure indicator of confidence in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline, their clinical trial data, and their chances of approval.
AKIMA Market Segment Index - General oncology therapy
Silexion Therapeutics (SLXN) is an early-stage oncology company focused on developing targeted cancer therapies, likely targeting new signaling pathways previously thought to be druggable. This chart shows the segment's average index, helping investors assess how this high-risk R&D strategy compares to the industry average.
The AKIM Index for the overall market
Silexion Therapeutics is a biotech company developing RNA interference (siRNA) therapies for cancer treatment targeting the KRAS oncogene. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this cutting-edge genetic technology compares to overall economic trends.
